For years, scientists believed that a group of brain cells known as agouti-related peptide, or AgRP, neurons played a straightforward role in metabolism: They stimulated hunger and resisted weight loss.
New research from Yale suggests the story is far more complicated.
In a study published in the Proceedings of the National Academy of Sciences (PNAS), researchers found that semaglutide, the active ingredient in Ozempic and other GLP-1 medications, appears to activate AgRP neurons rather than suppress them. Even more surprisingly, the study indicates that these hunger-promoting neurons may be necessary for maintaining the fat loss produced by the medication.
The findings challenge a long-standing assumption about the brain’s hunger circuitry and may help explain why newer GLP-1 therapies generate more substantial and lasting results than earlier weight-loss drugs.
Mateus d’Ávila, a Ph.D. candidate in neuroscience working in Tamas Horvath’s lab in the Department of Comparative Medicine at Yale School of Medicine (YSM) and first author of the study, said:
This completely changes how we think about the mechanism involved in these medications and provides new insight into the biology underlying their long-term effects, opening an avenue for the development of more efficient drugs.
The arrival of Ozempic and related GLP-1 therapies changed expectations, with some patients achieving sustained reductions of 10% to 15% of their body weight or more. Scientists know that these medications can reduce appetite and food intake. But appetite suppression alone may not fully account for their effectiveness.
Previous generations of weight-loss drugs could also substantially reduce hunger, yet they did not consistently produce the same degree of lasting weight loss as seen with semaglutide. That difference led the Yale team to suspect that GLP-1 medications were affecting additional biological systems.
One prominent theory held that the drugs worked partly by reducing the activity of AgRP neurons. Located in the brain’s hypothalamus, these neurons are strongly associated with hunger and feeding behavior. Because they encourage animals to seek and consume food, it seemed reasonable to assume that successful weight-loss treatments would need to inhibit them.
However, the role of AgRP neurons during long-term GLP-1 treatment had not been directly tested in a living organism. The Yale researchers set out to fill that gap.
Using a mouse model, the team combined several experimental approaches to examine what happened during semaglutide treatment. They tracked changes in body weight, food consumption, metabolism and energy expenditure.
The researchers also used genetic techniques to selectively remove or silence AgRP neurons. This allowed them to test whether the neurons merely responded to semaglutide or were actually required for the medication’s sustained effects.
The study results are striking. In mice genetically modified to lack AgRP neurons, GLP-1 treatment could initiate weight loss but could not sustain it. That suggested the neurons traditionally viewed as opponents of weight reduction were, in fact, helping preserve the drug’s long-term benefits.
Further investigations using electron microscopy, molecular biology and electrophysiology produced another unexpected finding: Semaglutide activated the AgRP neurons instead of inhibiting them. The researchers propose that this activation reflects the brain’s adaptation to the calorie deficit produced by GLP-1 treatment.
When calorie intake declines, AgRP neurons become more active as part of the body’s normal response to an energy shortage. Their best-known function is to increase hunger. The new study, however, suggests that their role is not limited to driving food intake. Under semaglutide treatment, the neurons may also participate in coordinating the loss of body fat.
In other words, the same neural system that signals a need for food may also help the body manage its energy stores during prolonged weight loss. This does not mean that hunger itself causes weight loss. Rather, it points to a previously unrecognized interaction between semaglutide, the brain’s response to calorie restriction, and the biological processes that determine whether lost weight stays off.
The discovery adds an important layer of complexity to scientists’ understanding of GLP-1 medications. Instead of simply shutting down the brain’s hunger signals, semaglutide may recruit parts of the hunger system and redirect their activity in ways that support sustained changes in body fat.
Because the study was conducted in mice, the results cannot yet be assumed to apply directly to humans. Researchers will need to determine whether the same neural mechanism operates in people taking semaglutide and other GLP-1 medications.
Still, identifying how the brain adapts during treatment could influence the next generation of obesity therapies. A more complete understanding of AgRP neurons might help scientists develop medications that preserve the benefits of GLP-1 drugs while improving their effectiveness, reducing unwanted effects, or helping a broader group of patients maintain weight loss.
d’Ávila said,
By identifying a previously unrecognized neural mechanism involved in sustaining weight loss, our work provides new biological insights that could eventually help researchers design therapies that are even more effective or have fewer side effects.
Your responses and feedback are welcome!
Source: “New study may change how we think about GLP-1s,” Yale News, 8/10/26
Source: “AgRP neurons are required for the weight-lowering effects of GLP-1 receptor agonists in female mice,” PNAS, 8/4/26
Image by denis1203.
FAQs and Media Requests: 
